Kyntra Bio Inc

Financials

Mittelzufluss aus laufender Geschäftstätigkeit 81.6 M-82.23 M-145.93 M-315.02 M-138 M-4.77 M -4.77 M Mittelzufluss aus Investitionstätigkeit 452.49 M-426.97 M89.12 M153.66 M125.99 M35.42 M 35.42 M Zahlungsströme aus der Finanzierungstätigkeit 13.34 M-563 K46.78 M122.75 M-255 K-86.03 M -86.03 M Freier Cashflow 77.61 M-87.42 M-149.67 M-317.54 M-138.26 M-4.81 M -4.81 M

Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate. On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB.